Angiogenic factors play a role in
tumor growth and spread. The object of this study was to analyze the correlation between
mRNA expression of angiogenesis-related genes and disease outcome in advanced-stage ovarian
carcinomas. Sections from 66 primary ovarian
carcinomas and metastatic lesions from 41 patients diagnosed with advanced stage ovarian
carcinoma (FIGO stages III-IV) were evaluated for expression of basic fibroblast factor (bFGF),
interleukin-8 (IL-8), and
vascular endothelial growth factor (
VEGF) using
mRNA In Situ Hybridization (ISH). Patients were divided in two groups based on disease outcome. Long-term survivors (17 patients) and short-term survivors (24 patients) were defined using a double cut-off of 36 months for disease-free survival (DFS) and 60 months for overall survival (OS). Mean follow-up period was 70 months. The mean values for DFS and OS were 116 and 133 months for long-term survivors, as compared to 3 and 21 months for short-term survivors, respectively. Expression of bFGF
mRNA, most often intense, was detected in
tumor and stromal cells in the majority of cases. Weak expression of
IL-8 mRNA was detected in both cell compartments, while
VEGF mRNA expression was limited to few cases. Primary
tumors displayed higher bFGF and
IL-8 mRNA expression. However, these differences did not reach statistical significance (P > 0.05). bFGF,
IL-8 and
VEGF mRNA expression in both
tumor and stromal cells was comparable in
tumors of long-term and short-term survivors, and showed no correlation with disease outcome in survival analysis (P > 0.05). bFGF is the major
angiogenic factor expressed in ovarian
carcinoma at the
mRNA level.
mRNA expression of
VEGF, bFGF, and
IL-8 does not appear to be a predictor of disease outcome in advanced-stage ovarian
carcinoma.